Compare Novavax Inc (NVAX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Yum China Holdings Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Yum China Holdings Inc trades at $42.92 (market cap $14.11B). The key difference: Yum China Holdings Inc is far larger — about 7.8× Novavax Inc's market cap, and Yum China Holdings Inc pays a 2.78% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Yum China Holdings Inc for 77 Days on average.
| NVAX | YUMC | |
|---|---|---|
Market Cap | $1.82B | $14.11B |
Volume | 6,198,505 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $57.95 |
52-Week Low | $6.22 | $39.98 |
Typical Hold Time | 59 Days | 77 Days |
Enterprise Value | $1.39B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
YUMC trades at $41.78, up 2.78% today, but technical indicators signal a bearish trend with strong sell signals from moving averages. Fundamentally, the company shows steady revenue growth, reaching $11.80B in 2025, with consistent earnings beats in recent quarters. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is mixed: strong analyst consensus (73.68% buy ratings) and a projected 25.63% upside suggest value, but bearish technicals and competitive pressures pose risks. Investors should weigh solid fundamentals against near-term price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
